Role of CXCR6/CXCL16 in Steatohepatitis

Medicine & Life Sciences

1. Alcoholic Hepatitis 100%
2. Non-alcoholic Fatty Liver Disease 77%
3. Liver 71%
4. CCR2 Receptors 55%
5. Bone Morphogenetic Protein 4 51%
6. Randomized Controlled Trials 51%
7. Liraglutide 50%
8. Transjugular Intrahepatic Portasystemic Shunt 49%
9. Liver Diseases 48%
10. Fibrosis 46%
11. Autoimmune Hepatitis 45%
12. Fatty Liver 42%
13. Portal Hypertension 39%
14. Myeloid Cells 36%
15. Virus Replication 36%
16. Hepacivirus 33%
17. Endothelium 31%
18. Insulin Resistance 29%
19. Systematic Reviews 26%
20. Survival 24%
21. Cohort Studies 24%
22. Guidelines 23%
23. Mortality 19%
24. Observational Studies 19%
25. Infections 17%
26. Vascular Endothelial Growth Factor Receptor 16%
27. Therapeutics 11%
28. Endothelial Cells 10%
29. Budd-Chiari Syndrome 9%
30. Virus Diseases 9%
31. Adrenal Cortex Hormones 9%
32. Biopsy 9%
33. Glucagon-Like Peptide 1 9%
34. Jugular Veins 8%
35. HLA-DRB1*03:01 antigen 8%
36. High Fat Diet 8%
37. Hepatocytes 7%
38. Portal Vein 7%
39. PubMed 7%
40. Ascites 7%
41. Histology 6%
42. Chronic Disease 6%
43. Metals 6%
44. Hypergammaglobulinemia 6%
45. Stents 6%
46. Bacteria 6%
47. Anti-Bacterial Agents 5%
48. Population 5%
49. Morbidity 5%
50. Research Ethics 5%
51. Obesity 5%
52. Placebos 5%
53. Immune Tolerance 5%
54. Kupffer Cells 5%
55. Biological Therapy 5%
56. Recurrence 5%
57. Azathioprine 5%